Thailand’s Public Health Ministry plans to establish a Health Marketplace connecting public-private services and improve healthcare access through data initiatives. It will attract foreign patients via flexible medical visas and partner with pharmaceutical companies through investment agreements requiring technology transfers and local manufacturing. An MSD agreement on HIV medicine production marks Thailand’s first major commitment to becoming a clinical research and manufacturing hub.
Key Points
Access and Revenue Enhancement:
- Health Marketplace platform to connect public and private healthcare services
- Data & Access initiative linking national health databases
- Improved i-Claim system for private insurance at public hospitals
- Target Thai, foreign, and overseas government patients from nearby regions (Bhutan, Maldives, South Asia)
- Flexible medical visas matching treatment duration with advance electronic appointments
Research and Development Hub:
- Attract 5+ billion baht in investment, increasing GDP by 0.05%
- One-Stop Approval mechanism for streamlined applications
- Fast Track & Regulatory Sandbox for accelerated innovation
- Establish Thailand as clinical research base with global partnerships
- Clinical trials and R&D initiatives to attract international investment
Manufacturing and Strategic Partnerships:
- Target 37 billion baht in new investment, increasing GDP by 0.25%
- Pharmaceutical Supply Chain Roadmap reducing import reliance
- Technology transfer programs with drugmakers
- Offset Policy requiring overseas suppliers to invest, transfer technology, or create employment
- MSD agreement as first “quick win” involving HIV medicine research and production
Healthcare Access and Medical Tourism Development
Thailand’s Public Health Ministry is implementing a comprehensive strategy to enhance healthcare accessibility and attract international patients. The initiative includes establishing a Health Marketplace that centralizes public and private healthcare services, alongside a Data & Access initiative linking national health databases to improve service delivery and inform policy decisions. The ministry will also upgrade i-Claim, the insurance reimbursement system for private claims at public hospitals. By targeting affluent Thai patients, foreign visitors, and overseas governments, particularly from neighboring regions like South Asia, Bhutan, and the Maldives, Thailand aims to generate sustainable revenue for its health system. A key proposal involves making medical visas more flexible to match individual treatment durations, while incorporating electronic appointments, advance referrals, and immigration data integration to streamline the patient experience and ensure security.
Market Expansion and Sector Collaboration
The ministry emphasized that both public and private sectors have substantial room to grow without direct competition. Thailand’s total healthcare spending reaches 4.59% of GDP, exceeding 800 billion baht, while public and private hospital sectors combined account for only one-third of this figure. Public Health Minister Pattana highlighted that the ministry’s budget totals 350-360 billion baht, compared to private hospital groups’ combined revenue of approximately 300 billion baht. This significant gap indicates enormous potential to attract additional healthcare spending through strategic market positioning. Rather than competing, the sectors can complement each other by serving different patient segments and expanding overall market capacity.
Research, Manufacturing, and International Investment
The ministry is positioning Thailand as a clinical research hub through the Research and Development Hub, targeting over 5 billion baht in new investment and 0.05% GDP growth. Initiatives include establishing a One-Stop Approval mechanism, implementing Fast Track & Regulatory Sandbox measures, and creating a Data & Research Platform. The manufacturing pillar aims to attract 37 billion baht in investment and achieve 0.25% GDP growth.
Through an Offset Policy, international pharmaceutical companies must reciprocate government procurement benefits via investments, technology transfers, or employment creation. Preliminary negotiations with ten global drugmakers, including Pfizer, Roche, and Novartis, have yielded MSD’s September 2026 memorandum of understanding to expand clinical research and transfer HIV medicine production technology to Thailand’s Government Pharmaceutical Organization, making Thailand one of only two countries producing this medicine.
